AtriCure

AtriCure to Announce First Quarter 2018 Financial Results

April 5, 2018

MASON, Ohio--(BUSINESS WIRE)--Apr. 5, 2018-- <u>AtriCure. Inc.</u> (<u>Nasdag: ATRC</u>), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2018 financial results on Thursday, April 26, 2018.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 26, 2018 to discuss its first quarter 2018 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 1288126. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator® Synergy[™] Ablation System is the first and only medical device to receiveFDA approval for the treatment of persistent Afib. AtriCure's AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 125,000 implanted to date. For more information, visit <u>AtriCure.com</u> or follow us on Twitter @<u>AtriCure</u>.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180405005012/en/

Source: AtriCure, Inc.

AtriCure, Inc. Andy Wade, 513-755-4564 Senior Vice President and Chief Financial Officer awade@atricure.com or Gilmartin Group Lynn Pieper Lewis, 415-937-5402 Investor Relations Lynn@gilmartinir.com